))
Permissive azotemia during AKI enables more rapid renal recovery and less renal fibrosis
Manage episode 363551543 series 3308934
Content provided by ESICM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ESICM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Preclinical models of acute kidney injury (AKI) consistently demonstrate that a uremic milieu enhances renal recovery and decreases kidney fibrosis.
Reduced renal clearance has the surprising and counterintuitive effect of being an effective treatment for AKI.
In this perspective, Dr Lakhmir S. Chawla suggests a hypothesis describing why the uremic milieu is kidney protective and proposes a clinical trial of ‘permissive azotemia’ to improve renal recovery and long-term renal outcomes in critically ill patients with severe AKI.
Hear more about the explanation of this hypothesis in the following podcast, organised by the ESICM AKI Section.
Speakers
Lakhmir S. CHAWLA. Chief Medical Officer, Silver Creek Pharmaceuticals. Recipient of the International Vicenza Award for Critical Care Nephrology.
Eric HOSTE. UZ Gent (BE). AKI Section Representative, ESICM Social Media & Digital Content Committee.
Marc ROMAIN. Hadassah Medical Center, Jerusalem (IL).
74 episodes
Share
